Dobson Lee, Sheldon Christopher D, Hattersley Andrew T
Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK.
J R Soc Med. 2004;97 Suppl 44(Suppl 44):26-35.
The limited available evidence supports the use of insulin treatment in CFRD. This fits with the dominant problem in CFRD being insulin deficiency and progressive beta cell dysfunction, making tablets that stimulate the beta cell unlikely to be a successful strategy. It is possible that patients with IGT or CFRD with moderate hyperglycaemia (e.g. relative preservation of fasting glucose) may initially respond to beta cell secretagogues. A large randomized prospective trial in the USA should answer this point in the next few years.
现有有限的证据支持在囊性纤维化相关糖尿病(CFRD)中使用胰岛素治疗。这与CFRD的主要问题相符,即胰岛素缺乏和进行性β细胞功能障碍,这使得刺激β细胞的片剂不太可能成为一种成功的策略。患有糖耐量受损(IGT)或伴有中度高血糖(例如空腹血糖相对保留)的CFRD患者可能最初会对β细胞促分泌剂有反应。美国一项大型随机前瞻性试验应会在未来几年回答这一问题。